HRP20171909T1 - Postupci i sastavi za otkrivanje razine djelovanja lizosomalne eksocitoze i načini njihove uporabe - Google Patents

Postupci i sastavi za otkrivanje razine djelovanja lizosomalne eksocitoze i načini njihove uporabe Download PDF

Info

Publication number
HRP20171909T1
HRP20171909T1 HRP20171909TT HRP20171909T HRP20171909T1 HR P20171909 T1 HRP20171909 T1 HR P20171909T1 HR P20171909T T HRP20171909T T HR P20171909TT HR P20171909 T HRP20171909 T HR P20171909T HR P20171909 T1 HRP20171909 T1 HR P20171909T1
Authority
HR
Croatia
Prior art keywords
composition
use according
polypeptide
neu1
individual
Prior art date
Application number
HRP20171909TT
Other languages
English (en)
Inventor
Ida ANNUNZIATA
Alessandra D'azzo
Shai WHITE-GILBERTSON
Original Assignee
St. Jude Children's Research Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by St. Jude Children's Research Hospital filed Critical St. Jude Children's Research Hospital
Publication of HRP20171909T1 publication Critical patent/HRP20171909T1/hr

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/40—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/005—Sugars; Derivatives thereof; Nucleosides; Nucleotides; Nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/16—Serine-type carboxypeptidases (3.4.16)
    • C12Y304/16005—Carboxypeptidase C (3.4.16.5), i.e. carboxypeptidase Y
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10031—Uses of virus other than therapeutic or vaccine, e.g. disinfectant
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Claims (10)

1. Sastav, naznačen time, da obuhvaća polipeptid zaštitnog proteina/katepsina A (PPCA-polipeptid) ili jednu njegovu djelatnu varijantu ili jedan njegov fragment, pri čemu taj polipeptid, njegova djelatna varijanta ili njegov fragment, obuhvaća aminokiselinsku sekvencu s najmanje 85% identiteta sekvence od SEQ ID NO: 4, i on poboljšava enzimsko djelovanje neuraminidaze 1 (NEU1), čime se upotrebljava u postupku liječenja ili prevencije demencije povezane s Alzheimerovom bolešću kod pojedinca, gdje postupak obuhvaća davanje pojedincu terapeutski učinkovite količine ovog sastava.
2. Sastav za uporabu prema zahtjevu 1, naznačen time, da sastav obuhvaća PPCA koji ima aminokiselinsku sekvencu od SEQ ID NO: 4.
3. Sastav za uporabu prema zahtjevu 1, naznačen time, da se sastav u postupku primjenjuje u kombinaciji s polipeptidom neuraminidaze 1 (NEU1-polipeptidom) ili s njegovom djelatnom varijantom ili njegovim fragmentom, pri čemu NEU1-polipeptid, njegova djelatna varijanta ili njegov fragment, obuhvaća aminokiselinsku sekvencu s najmanje 85% identiteta sekvence od SEQ ID NO: 2, te također ima djelotvornost sialidaze.
4. Sastav za uporabu prema zahtjevu 3, naznačen time, da se PPCA i NEU1 primjenjuju odvojeno.
5. Sastav za uporabu prema zahtjevu 3, naznačen time, da se PPCA i NEU1 primjenjuju istovremeno.
6. Sastav za uporabu prema zahtjevu 3, naznačen time, da se u postupku primjenjuje NEU1-polipeptid koji ima aminokiselinsku sekvencu od SEQ ID NO: 2.
7. Sastav za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time, da pojedinac je sisavac.
8. Sastav za uporabu prema zahtjevu 7, naznačen time, da pojedinac je čovjek.
9. Sastav za uporabu prema bilo kojem od zahtjeva 1 do 8, naznačen time, da se sastav u postupku daje pojedincu istovremeno ili uzastopno zajedno s jednim ili više dodatnih lijekova za liječenje Alzheimerove bolesti.
10. Sastav za uporabu prema zahtjevu 9, naznačen time, da je dodatni lijek za liječenje Alzheimerove bolesti, odabran iz skupine koju čine donepezil, galantamin, memantin, rivastigmin i takrin.
HRP20171909TT 2011-08-31 2017-12-08 Postupci i sastavi za otkrivanje razine djelovanja lizosomalne eksocitoze i načini njihove uporabe HRP20171909T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161529675P 2011-08-31 2011-08-31
US201161544855P 2011-10-07 2011-10-07
PCT/US2012/052629 WO2013033074A2 (en) 2011-08-31 2012-08-28 Methods and compositions to detect the level of lysosomal exocytosis activity and methods of use
EP12761845.2A EP2751279B1 (en) 2011-08-31 2012-08-28 Methods and compositions to detect the level of lysosomal exocytosis activity and methods of use

Publications (1)

Publication Number Publication Date
HRP20171909T1 true HRP20171909T1 (hr) 2018-01-26

Family

ID=46881159

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20171909TT HRP20171909T1 (hr) 2011-08-31 2017-12-08 Postupci i sastavi za otkrivanje razine djelovanja lizosomalne eksocitoze i načini njihove uporabe

Country Status (15)

Country Link
US (5) US9399791B2 (hr)
EP (1) EP2751279B1 (hr)
JP (1) JP6228121B2 (hr)
AU (1) AU2012300252B2 (hr)
CA (1) CA2847057C (hr)
CY (1) CY1119689T1 (hr)
DK (1) DK2751279T3 (hr)
ES (1) ES2653918T3 (hr)
HR (1) HRP20171909T1 (hr)
HU (1) HUE037829T2 (hr)
LT (1) LT2751279T (hr)
PL (1) PL2751279T3 (hr)
PT (1) PT2751279T (hr)
SI (1) SI2751279T1 (hr)
WO (1) WO2013033074A2 (hr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2477884T3 (es) 2008-08-19 2014-07-18 Xenoport, Inc. Profármacos de hidrogenofumarato de metilo, composiciones farmacéuticas de los mismos y procedimientos de uso
CA2882713A1 (en) 2012-08-22 2014-02-27 Xenoport, Inc. Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
WO2014031897A1 (en) 2012-08-22 2014-02-27 Xenoport, Inc. Oral dosage forms having a high loading of (n,n- diethylcarbamoyl)methyl methyl|(2e)but-2-ene-1,4-dioate
WO2014160633A1 (en) 2013-03-24 2014-10-02 Xenoport, Inc. Pharmaceutical compositions of dimethyl fumarate
WO2014197860A1 (en) 2013-06-07 2014-12-11 Xenoport, Inc. Method of making monomethyl fumarate
US9421182B2 (en) 2013-06-21 2016-08-23 Xenoport, Inc. Cocrystals of dimethyl fumarate
TW201516020A (zh) 2013-09-06 2015-05-01 Xenoport Inc （ｎ，ｎ－二乙基胺甲醯基）甲基（２ｅ）丁－２－烯－１，４－二酸甲酯之晶形、合成方法及用途
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
WO2016179481A1 (en) * 2015-05-07 2016-11-10 Cardelli James Allen Cancer treatment via repositioned tricyclic anti-depressant-like drugs as anti-cancer agents and new combinations of such drugs
BR112018008839A8 (pt) * 2015-10-30 2019-02-26 Ultragenyx Pharmaceutical Inc métodos e composições para o tratamento da amiloidose
US20210198689A1 (en) * 2016-03-18 2021-07-01 Nant Holdings Ip, Llc Multimodal Vector for Dendritic Cell Infection
BR112019013843A2 (pt) * 2017-01-04 2020-01-28 Ericsson Telefon Ab L M método e estação base para transmitir informações do sistema, método e equipamento de usuário para receber informações do sistema e meio de armazenagem legível por computador
CA3145622A1 (en) 2019-07-05 2021-01-14 Tokushima University Modified neuraminidase
WO2023147605A2 (en) * 2022-01-31 2023-08-03 Sens Research Foundation Senescent cell surface markers

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769331A (en) 1981-09-16 1988-09-06 University Patents, Inc. Recombinant methods and materials
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
US5288641A (en) 1984-06-04 1994-02-22 Arch Development Corporation Herpes Simplex virus as a vector
US4859587A (en) 1984-06-04 1989-08-22 Institut Merieux Recombinant herpes simplex viruses, vaccines and methods
NL8720442A (nl) 1986-08-18 1989-04-03 Clinical Technologies Ass Afgeefsystemen voor farmacologische agentia.
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5328688A (en) 1990-09-10 1994-07-12 Arch Development Corporation Recombinant herpes simplex viruses vaccines and methods
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
AU1115797A (en) 1995-10-26 1997-05-15 Alessandra D'azzo Protective protein/cathepsin a and precursor: crystallization, x-ray diffraction, three-dimensional structure determination and rational drug design
WO1998031817A2 (en) * 1997-01-14 1998-07-23 Hopital Sainte-Justine Human lysosomal sialidase and therapeutic uses thereof
ES2323940T3 (es) * 2000-05-01 2009-07-28 Accera, Inc. Uso de trigliceridos de cadena media para el tratamiento y prevencion de la enfermedad de alzheimer.
US7232670B2 (en) 2001-09-28 2007-06-19 St. Jude Children's Research Hospital Targeting proteins to cells expressing mannose receptors via expression in insect cells
AU2004290298A1 (en) 2003-10-24 2005-05-26 Gilead Sciences, Inc. Methods and compositions for identifying therapeutic compounds
WO2006013013A2 (en) 2004-08-04 2006-02-09 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with protective protein for beta-galactosidase (ppgb)
US20110166074A1 (en) 2006-10-18 2011-07-07 Cornell Research Foundation, Inc. Cln2 treatment of alzheimer's disease
US7951367B2 (en) 2006-11-15 2011-05-31 The J. David Gladstone Institutes Methods and compositions for reducing amyloid beta levels
US8420613B2 (en) 2006-11-15 2013-04-16 The J. David Gladstone Institutes Methods and compositions for reducing amyloid beta levels
ES2635726T3 (es) 2007-06-06 2017-10-04 Genzyme Corporation Terapia génica para enfermedades de almacenamiento lisosómico
DK2490712T3 (en) * 2009-10-19 2015-10-05 Amicus Therapeutics Inc PROCESS FOR THE TREATMENT OF ALZHEIMER'S DISEASE BY USING Pharmacological chaperones TO INCREASE ACTIVITY OF GANGLIOSIDASER
US20140161896A1 (en) 2011-08-04 2014-06-12 Ramot At Tel-Aviv University Ltd. Particles for the treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
EP2751279B1 (en) 2017-10-04
US20160304933A1 (en) 2016-10-20
US10533208B2 (en) 2020-01-14
US20140377245A9 (en) 2014-12-25
JP6228121B2 (ja) 2017-11-08
CA2847057A1 (en) 2013-03-07
US20140193392A1 (en) 2014-07-10
AU2012300252B2 (en) 2017-10-19
CY1119689T1 (el) 2018-04-04
SI2751279T1 (en) 2018-01-31
LT2751279T (lt) 2017-12-11
CA2847057C (en) 2019-06-11
DK2751279T3 (da) 2017-11-20
PL2751279T3 (pl) 2018-03-30
PT2751279T (pt) 2017-12-29
US20220406435A1 (en) 2022-12-22
US9399791B2 (en) 2016-07-26
US20200087704A1 (en) 2020-03-19
US9840727B2 (en) 2017-12-12
WO2013033074A3 (en) 2013-04-25
EP2751279A2 (en) 2014-07-09
JP2014526904A (ja) 2014-10-09
US20180057854A1 (en) 2018-03-01
ES2653918T3 (es) 2018-02-09
WO2013033074A2 (en) 2013-03-07
AU2012300252A1 (en) 2014-03-20
HUE037829T2 (hu) 2018-09-28

Similar Documents

Publication Publication Date Title
HRP20171909T1 (hr) Postupci i sastavi za otkrivanje razine djelovanja lizosomalne eksocitoze i načini njihove uporabe
HRP20191291T1 (hr) Imunogeni pripravak
BR112015010396A2 (pt) terapia de combinação
JP2015517488A5 (hr)
WO2008054540A3 (en) Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
WO2014165607A3 (en) Aromatic-cationic peptide formulations, compositions and methods of use
WO2015183963A3 (en) Therapeutic compositions including redox-active parabenzoquinones and uses thereof
JP2014526904A5 (hr)
HRP20160392T1 (hr) Cjepivo pcsk9
HRP20150317T1 (hr) Peptidi trave za cjepivo
MA35513B1 (fr) Compositions pharmaceutiques comprenant 40 - o - ( 2 - hydroxy) éthyl - rapamycine
JP2013503165A5 (hr)
PE20140617A1 (es) Alfa glucosidasa acida modificada con procesamiento acelerado
BR112018005905A2 (pt) ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto?
HRP20150664T1 (hr) Antikancerogeni fuzijski protein
BR112013001753A2 (pt) método para preparar uma composição d einter-alfa-inibidor (iaip) eriquecida de plasma, solução aquosa de iaip, e, método para tratar uma doença ou distúrbio associado com disfunção de iaip e associado com atividadede protease de serina no plasma aumentada.
BR112016024020A8 (pt) composição farmacêutica
BR112014017141A2 (pt) método de tratamento de diabetes usando-se apolipoproteína a-iv não glicosilada
AR106538A1 (es) Métodos y composiciones para el tratamiento de la amiloidosis
RU2018124487A (ru) Лечение внутрипеченочного холестаза и родственных заболеваний печени
DE112004000961D2 (de) Verwendung von Wirksubstanzen zur Vorbeugung oder Behandlung von Viruserkrankungen sowie Testsystem zum Auffinden solcher Wirksubstanzen
WO2009047513A3 (en) Antagonists of kisspeptin and uses thereof
WO2011059263A3 (ko) 뇌혈관 장벽을 통과하여 퇴행성 뇌신경 질환 부위의 세포사멸을 표적하는 펩타이드 및 이의 용도
CL2014003607A1 (es) Compuestos derivados de benzodioxol, inhibidores de la acetilcolinesterasa; metodo de preparacion; compuestos intermediarios; composicion farmaceutica; y uso en la prevencion o el tratamiento de la enfermedad de alzheimer.
CL2018002768A1 (es) Formulaciones que comprenden alfa-glucosidasa ácida recombinante